Skip to content

Effect of Self-administered Smoke or Smokeless Moxibustion on Breech Presentation Converting to Cephalic Presentation

Effect of Self-administered Smoke or Smokeless Moxibustion on Breech Presentation Converting to Cephalic Presentation - Smoke or Smokeless Moxibustion for Breech Presentation: A quasi-experimental study

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000021377
Enrollment
60
Registered
2016-03-07
Start date
2016-03-07
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pregnant women with a singleton breech presentation between 33 and 35 weeks of gestation

Interventions

Interventions : A To stimulate the acupoint BL67 by moxibustion (smoke moxa sticks ) for 20 minutes each time, once or twice daily for 10-14 days Interventions : B To stimulate the acupoint BL67 b

Sponsors

St. Luke's International University
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1.Pregnant women with a singleton breech presentation between 33 and 35 weeks of gestation. 2.Normal fetal biometry, and normal pregnancy progress 3.Japanese women aged greater than 18 years.

Exclusion criteria

Exclusion criteria: 1.Pregnancy with multiples beyond twins, risk of preterm birth (preterm uterine contractions and/or initial dilatation or shortening of the cervix with a score of 4 on the Bishop scale, tocolytic therapy), uterine fibroids > 4cm, maternal heart or kidney disease, placenta previa, complications with pregnancy-induced hypertension, pre-labor rupture of the membranes, contraindication to vaginal delivery, intrauterine growth restriction, fetal malformation or chromosomal disorder, pregnant woman or siblings of the fetus diagnosed with bronchial asthma or a pulmonary problem, and is treated (only in the intervention group) 2.previous uterine surgery, uterine malformations, bone pelvic defects, allergies of Artemisia vulgaris (only in the intervention group), pregnant woman or siblings of the fetus who have symptoms of coughing, respiratory discomfort by smoke (only in the intervention group) 3.prior treatment with moxibustion to achieve version of the fetus

Design outcomes

Primary

MeasureTime frame
Cephalic presentations at two weeks after the start of interventions.

Secondary

MeasureTime frame
(1) Cephalic presentations at birth (excluding external cephalic version) (2) Birthing outcomes (the mode of birth, premature birth requiring hospitalization, preterm birth, pre-labor rupture of membranes at < 37 weeks, gestational age at birth, Apgar score < 7 at 5 min., birthweight, admission to NICU, cord blood pH less than 7.1, perinatal morbidity and mortality, (3) The number of self-reported fetal movements. (4) Side effects from using moxa sticks

Countries

Japan

Contacts

Public ContactAkiko Higashihara

St.Luke's International University Graduate School Science in nursing, Women's Health & Midwifery

14dn012@slcn.ac.jp03-6226-6361

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026